{
    "id": 17308,
    "fullName": "TP53 R280K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "TP53 R280K lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R280K results in decreased activation and repression of wild-type Tp53 target genes (PMID: 17070499, PMID: 16322760, PMID: 18472962), as well as a gain-of-function in activation of novel targets, and leads to increased cell migration and invasion, and increased cell survival (PMID: 18472962, PMID: 24763051).",
            "references": [
                {
                    "id": 4536,
                    "pubMedId": 18472962,
                    "title": "Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18472962"
                },
                {
                    "id": 4476,
                    "pubMedId": 24763051,
                    "title": "A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24763051"
                },
                {
                    "id": 12516,
                    "pubMedId": 16322760,
                    "title": "p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16322760"
                },
                {
                    "id": 2397,
                    "pubMedId": 22713868,
                    "title": "Mutant p53: one name, many proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22713868"
                },
                {
                    "id": 12515,
                    "pubMedId": 17070499,
                    "title": "Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17070499"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "R280K",
    "createDate": "01/27/2016",
    "updateDate": "10/09/2018",
    "referenceTranscriptCoordinates": {
        "id": 95489,
        "transcript": "NM_000546",
        "gDna": "chr17:g.7673781C>T",
        "cDna": "c.839G>A",
        "protein": "p.R280K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6021,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620).",
            "molecularProfile": {
                "id": 17595,
                "profileName": "TP53 R280K"
            },
            "therapy": {
                "id": 4006,
                "therapyName": "YW3-56",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5233,
                    "pubMedId": 25612620,
                    "title": "ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25612620"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5012,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011).",
            "molecularProfile": {
                "id": 17595,
                "profileName": "TP53 R280K"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4831,
                    "pubMedId": 26009011,
                    "title": "Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26009011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9803,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically in culture, resulting in reduced cell viability in patient derived ovarian cancer cells harboring TP53 R280K (PMID: 27179933).",
            "molecularProfile": {
                "id": 17595,
                "profileName": "TP53 R280K"
            },
            "therapy": {
                "id": 3443,
                "therapyName": "APR-246 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7621,
                    "pubMedId": 27179933,
                    "title": "Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27179933"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10456,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, the combination of Afinitor (everolimus) and Taxol (paclitaxel) resulted in a partial response lasting over 13 months in a metastatic urothelial carcinoma patient harboring NF2 Y153fs*1, as well as ATM V2119fs*8, an ATR splice site mutation, and TP53 R280K, who had progressed on platinum-based chemotherapy and single agent Taxotere (docetaxel) therapy (PMID: 25630452).",
            "molecularProfile": {
                "id": 27471,
                "profileName": "ATM V2119fs ATR mut NF2 Y153fs TP53 R280K"
            },
            "therapy": {
                "id": 5505,
                "therapyName": "Everolimus + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8466,
                    "pubMedId": 25630452,
                    "title": "Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25630452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17595,
            "profileName": "TP53 R280K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27471,
            "profileName": "ATM V2119fs ATR mut NF2 Y153fs TP53 R280K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 95491,
            "transcript": "NM_001126114",
            "gDna": "chr17:g.7673781C>T",
            "cDna": "c.839G>A",
            "protein": "p.R280K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95489,
            "transcript": "NM_000546",
            "gDna": "chr17:g.7673781C>T",
            "cDna": "c.839G>A",
            "protein": "p.R280K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95488,
            "transcript": "NM_001126112",
            "gDna": "chr17:g.7673781C>T",
            "cDna": "c.839G>A",
            "protein": "p.R280K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 95490,
            "transcript": "NM_001126113",
            "gDna": "chr17:g.7673781C>T",
            "cDna": "c.839G>A",
            "protein": "p.R280K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}